Previous 10 | Next 10 |
Introduction In Trump's 2019 State of the Union Address, the topic of eradicating HIV morphed into a campaign promise with HIV poster child Gilead ( GILD ) getting most of the accolades due to their advances in prevention drugs. Almost 9 months later (last month), the Trump administration ...
Pfizer ( PFE ) shares have struggled this year as the company works to redefine what its sole focus on the future will be. New CEO, Albert Bourla, is making a bet that Pfizer's shareholders will be best served by focusing on brand name drugs. In that spirit, the company has already announced i...
A lot is changing for two of the biggest drugmakers on the planet. Pfizer (NYSE: PFE) is merging its Upjohn business with Mylan (NASDAQ: MYL) . Bristol-Myers Squibb (NYSE: BMY) just completed its acquisition of Celgene. Investors have rewarded Bristol-Myers Squibb's moves more so f...
As we push deeper into December, small-cap stocks and mid-cap stocks could begin marching higher in line with the January effect, a period during which large cap typically lags as institutional investors use the year's fresh slate to restructure portfolios for greater returns. Although the Rus...
Takeover bids offering a 245% premium over Sorrento Therapeutics 's (NASDAQ: SRNE) $1.45 share price last month might seem like a seize-the-day sort of moment. Especially considering Sorrento's financial situation. The company's earnings missed analyst estimates for the past four q...
Shares of Revance Therapeutics (NASDAQ: RVNC) are under pressure after management announced the pricing of a secondary offering. Investors dismayed by the pricing of the offering have hammered the biotech stock 16.4% lower as of 12:07 p.m. EST on Wednesday. Revance shares had been climbin...
Mylan N.V. (MYL) Evercore ISI 2nd Annual HealthCONx Conference December 03, 2019 11:00 AM ET Company Participants Ken Parks - Chief Financial Officer Rajiv Malik - President Conference Call Participants Umer Raffat - Evercore ISI Presentation Umer Raffat Thank you a...
HERTFORDSHIRE, England , PITTSBURGH and BENGALURU, India , Dec. 2, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin &...
Never laugh at live dragons. ― J.R.R. Tolkien Mylan has been in the market for 60 years now and is now one of the World’s largest generics manufacturers. It generated about $11 Billion in revenues last year. The business has always had thin margins, but the company gen...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...